Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- Kessel, Maura & Hannemann-Weber, Henrike & Kratzer, Jan, 2012. "Innovative work behavior in healthcare: The benefit of operational guidelines in the treatment of rare diseases," Health Policy, Elsevier, vol. 105(2), pages 146-153.
- Nicole B. Simpson, 2022.
"Demographic and economic determinants of migration,"
IZA World of Labor, Institute of Labor Economics (IZA), pages 373-373, July.
- Nicole B. Simpson, 2017. "Demographic and economic determinants of migration," IZA World of Labor, Institute of Labor Economics (IZA), pages 373-373, June.
- Patrizio Armeni & Marianna Cavazza & Entela Xoxi & Domenica Taruscio & Yllka Kodra, 2021. "Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal," IJERPH, MDPI, vol. 18(3), pages 1-18, January.
- Michael Drummond & Adrian Towse, 2014. "Orphan drugs policies: a suitable case for treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 335-340, May.
- Belousova, Olga A. & Groen, Aard J. & Ouendag, Aniek M., 2020. "Opportunities and barriers for innovation and entrepreneurship in orphan drug development," Technological Forecasting and Social Change, Elsevier, vol. 161(C).
- Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
- Lundberg, Ian & Brand, Jennie E. & Jeon, Nanum, 2022. "Researcher reasoning meets computational capacity: Machine learning for social science," SocArXiv s5zc8, Center for Open Science.
- Javier Orofino & Javier Soto & Miguel Casado & Itziar Oyagüez, 2010. "Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007," Applied Health Economics and Health Policy, Springer, vol. 8(5), pages 301-315, September.
- Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294.
- Elżbieta Szaruga & Elżbieta Załoga, 2022. "Qualitative–Quantitative Warning Modeling of Energy Consumption Processes in Inland Waterway Freight Transport on River Sections for Environmental Management," Energies, MDPI, vol. 15(13), pages 1-21, June.
- Jonathan Cortés-Martín & Lourdes Díaz-Rodríguez & Beatriz Piqueras-Sola & Raquel Rodríguez-Blanque & Antonio Bermejo-Fernández & Juan Carlos Sánchez-García, 2020. "Hajdu–Cheney Syndrome: A Systematic Review of the Literature," IJERPH, MDPI, vol. 17(17), pages 1-18, August.
- Linda Yamoah & Nick Dragojlovic & Alesha Smith & Larry D. Lynd & Carlo A. Marra, 2021. "Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions," PharmacoEconomics, Springer, vol. 39(1), pages 109-119, January.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Reza Mahjoub & Fredrik Ødegaard & Gregory S. Zaric, 2018. "Evaluation of a pharmaceutical risk‐sharing agreement when patients are screened for the probability of success," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 15-25, January.
- Alan J. Girling & Richard J. Lilford & Terry P. Young, 2012. "Pricing Of Medical Devices Under Coverage Uncertainty—A Modelling Approach," Health Economics, John Wiley & Sons, Ltd., vol. 21(12), pages 1502-1507, December.
- Puig-Junoy, Jaume & López-Valcárcel, Beatriz González, 2014. "Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995–2007," Health Policy, Elsevier, vol. 116(2), pages 170-181.
- Degtiar, Irina, 2017. "A review of international coverage and pricing strategies for personalized medicine and orphan drugs," Health Policy, Elsevier, vol. 121(12), pages 1240-1248.
- Jeremy D. Goldhaber-Fiebert & Lauren E. Cipriano, 2023. "Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis," Medical Decision Making, , vol. 43(7-8), pages 914-929, October.
- Serdar Öztürk & Buket Altınöz, 2022. "An Investigation of the Impact of Health Expenditures on International Migration as a Pull Factor in OECD Countries Using a Panel Vector Autoregression (PVAR) Approach," Journal of Economic Policy Researches, Istanbul University, Faculty of Economics, vol. 9(1), pages 39-52, January.
- Inese Mavlutova & Dzintra Atstaja & Janis Grasis & Jekaterina Kuzmina & Inga Uvarova & Dagnija Roga, 2023. "Urban Transportation Concept and Sustainable Urban Mobility in Smart Cities: A Review," Energies, MDPI, vol. 16(8), pages 1-16, April.
- Nicod, Elena & Annemans, Lieven & Bucsics, Anna & Lee, Anne & Upadhyaya, Sheela & Facey, Karen, 2019. "HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries," Health Policy, Elsevier, vol. 123(2), pages 140-151.
- Witsarut Achariyaviriya & Wongkot Wongsapai & Kittitat Janpoom & Tossapon Katongtung & Yuttana Mona & Nakorn Tippayawong & Pana Suttakul, 2023. "Estimating Energy Consumption of Battery Electric Vehicles Using Vehicle Sensor Data and Machine Learning Approaches," Energies, MDPI, vol. 16(17), pages 1-14, September.
- Oudom Hean, 2022. "The Effects of Technological Progress in Innovative Regions on the Labor Markets of Lagging Regions: A Theoretical Perspective," Economies, MDPI, vol. 10(8), pages 1-12, August.
- Elżbieta Szaruga & Bartosz Pilecki & Marta Sidorkiewicz, 2023. "The Impact of the COVID-19 Pandemic, Transport Accessibility, and Accommodation Accessibility on the Energy Intensity of Public Tourist Transport," Energies, MDPI, vol. 16(19), pages 1-27, October.
- Veronika Kalouguina & Joël Wagner, 2020. "Challenges and Solutions for Integrating and Financing Personalized Medicine in Healthcare Systems: A Systematic Literature Review," JRFM, MDPI, vol. 13(11), pages 1-22, November.
- Michael Drummond & Aleksandra Torbica & Rosanna Tarricone, 2020. "Should health technology assessment be more patient centric? If so, how?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1117-1120, November.
- Moors, Ellen H.M. & Kukk Fischer, Piret & Boon, Wouter P.C. & Schellen, Frank & Negro, Simona O., 2018. "Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands," Technological Forecasting and Social Change, Elsevier, vol. 128(C), pages 133-143.
- Amr Abdelwahed & Anne Goujon & Leiwen Jiang, 2020. "The Migration Intentions of Young Egyptians," Sustainability, MDPI, vol. 12(23), pages 1-38, November.
- Serina Chang & Adam Fourney & Eric Horvitz, 2024. "Measuring vaccination coverage and concerns of vaccine holdouts from web search logs," Nature Communications, Nature, vol. 15(1), pages 1-21, December.
- Letycja Sołoducho-Pelc & Adam Sulich, 2022. "Natural Environment Protection Strategies and Green Management Style: Literature Review," Sustainability, MDPI, vol. 14(17), pages 1-25, August.
- Rodica Pripoaie & Carmen-Mihaela Cretu & Anca-Gabriela Turtureanu & Carmen-Gabriela Sirbu & Emanuel Ştefan Marinescu & Laurentiu-Gabriel Talaghir & Florentina Chițu & Daniela Monica Robu, 2022. "A Statistical Analysis of the Migration Process: A Case Study—Romania," Sustainability, MDPI, vol. 14(5), pages 1-27, February.
- Paulo Reis Mourao, 2021. "Footsteps in the sand: studying refugee paths since 2005 through a network analysis of 205 territories," Quality & Quantity: International Journal of Methodology, Springer, vol. 55(2), pages 563-600, April.
- Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur, 2016. "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation," PharmacoEconomics, Springer, vol. 34(3), pages 285-301, March.
More about this item
Keywords
health emigration; rare disease; orphan drug; access gap; discrimination in access to therapy;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:3:p:2483-:d:1051758. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.